The Hindu Business Line : Ranbaxy to sell Doxycycline in US

Ranbaxy Laboratories Ltd has announced that the company has received approval from the US Food and Drug Administration (FDA) to manufacture and market Doxycycline Tablets — 50 mg, 75 mg, and 100 mg in the US market. The Office of Generic Drugs, FDA has determined the Ranbaxy formulation to be bio-equivalent and have the same therapeutic effect as that of the branded drug Adoxa, marketed by Bioglan Pharmaceutical Co. Annualised market sales for Adoxa were $57.2 million of the Doxycycline market, which achieved sales of $62.7 million (IMS - MAT: March 2006). Doxycycline is indicated for a variety of infections caused by susceptible strains of micro-organisms including respiratory tract and urinary tract infections, skin and skin structure infections, and severe acne as adjunctive therapy.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
BV Biologicals to offer manufacturing facilities

ONGC to relent on GE Shipping de-merger

UTI MF buys 2.23% in Rain Calcining

SAIL plants lining up new oxygen units

Ranbaxy to sell Doxycycline in US

Tata Power may join Tata Steel for coal mining

ONGC may pick 30% stake in Assam-Arakan project

TVS Motor overall growth at 17%

IndianOil plans to import 40.9 mt crude oil in '06-07

GAIL favours cost of service method for computing tariff

Kingfisher Air plans to raise $200 m via IPO or FCCB route

Purani to expand yarn production capacity

Panna-Mukta jt venture yet to firm up crude offtake pact